Myeloproliferative Neoplasms
Reactive oxygen species levels decreased and patients with evident bone marrow failure showed hematological response.
The agent targets abnormal gene expression in order to control the excessive cell proliferation that occurs in PV.
Adrián Mosquera Orgueira, MD, PhD, spoke of his team's study into machine learning tools for improving risk stratification.
In a phase 1 trial the product performed favorably in aplastic anemia, myelofibrosis, and hypoplastic myelodysplasia.
Investigational T-Cell Immunotherapy Superior to Standard HSCT in Rate of Survival Plus GvHD Freedom
A phase 3 study comparing the treatments in multiple hematologic malignancies also saw greater overall survival at one year.
The hepcidin mimetic increased hematocrit control and reduced both phlebotomy need and symptoms in a phase 2 trial.
Thrombosis history was not predictive of overall survival in patients with pulmonary hypertension risk and PV, a study found.
The panel's discussion, moderated by Neil Love, MD, dove especially into the nuances of using avapritinib and ruxolitinib.
Detectable MRD before HSCT is associated with worse survival in patients with MDS/MPN compared with undetectable MRD.
This novel JAK2 inhibitor features reduced off-target suppression of JAK1, JAK3, TYK2, and other kinases.
Advertisement
Expert Interviews on Hematology
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.